A Randomized Trial of Single- and Two-Dose Ivermectin versus Thiabendazole for Treatment of Strongyloidiasis
A randomized trial is described comparing ivermectin and thiabendazole for treatment of chronic infection with Strongyloides stercoralis. Subjects received ivermectin (200 µg/kg) in a single dose, ivermectin (200 µg/kg) on 2 consecutive days, or thiabendazole (50 mg/kg/day) twice daily for 3 consecu...
Gespeichert in:
Veröffentlicht in: | The Journal of infectious diseases 1994-05, Vol.169 (5), p.1076-1079 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | A randomized trial is described comparing ivermectin and thiabendazole for treatment of chronic infection with Strongyloides stercoralis. Subjects received ivermectin (200 µg/kg) in a single dose, ivermectin (200 µg/kg) on 2 consecutive days, or thiabendazole (50 mg/kg/day) twice daily for 3 consecutive days. Most subjects (94%) had intermittent symptoms, including urticaria, epigastric pain, and diarrhea. Stools were examined 7 days and 1, 3, 6, 10, and 22 months after treatment. Fifty-three subjects completed at least 3 months of follow-up. Only 1 of 34 and 2 of 19 ivermectin and thiabendazole subjects, respectively, had a stool positive for larvae after treatment. Symptoms were relieved in all 3 groups and eosinophil levels returned to normal in 90% of all subjects by 12 months. Nearly 95% of thiabendazole subjects had short-term adverse effects during therapy versus only 18% of those treated with ivermectin. One dose of ivermectin provides safety and efficacye quivalent to thiabendazole with a much lower prevalence of side effects and, consequently, better compliance. |
---|---|
ISSN: | 0022-1899 1537-6613 |
DOI: | 10.1093/infdis/169.5.1076 |